Deciding on the right path for opioid use disorder treatment is a deeply personal choice, and it’s one of the most important decisions you can make for yourself or a loved one. You’re likely looking for a solution that not only helps manage cravings and withdrawal but also fits into your life, allowing you to focus on healing without the daily reminder of medication.
That’s where the Sublocade injection comes in. It’s a once-monthly treatment that’s gaining attention, but you probably have a lot of questions. Is it effective? What are the side effects? How does it even work? We understand the weight of these questions. Here, we’ll walk through those answers together, offering clear, straightforward information to help you see if Sublocade could be the right fit for your recovery journey.
How does Sublocade work?
Thinking about how a medication works inside your body can feel complicated, but the idea behind the Sublocade injection is actually quite simple and powerful. Sublocade is an extended-release form of buprenorphine, a medication that has been a cornerstone of medication-assisted treatment (MAT) for years. It’s designed specifically for adults with moderate to severe opioid use disorder.
buprenorphine is what’s known as a “partial opioid agonist.” It’s a bit like a key that fits into a lock (the opioid receptors in your brain) but doesn’t turn it all the way. It gently stimulates these receptors just enough to reduce withdrawal symptoms and cravings, but not enough to produce the euphoric “high” that full opioids do. At the same time, by occupying those receptors, it effectively blocks other opioids from attaching, which can help prevent relapse.
The steady level of medication helps you feel more stable, so you can focus on the other important parts of your recovery. This approach is a key part of effective opioid addiction treatment. In a clinical study, 28% of patients receiving Sublocade along with counseling found treatment success, compared to just 2% who received a placebo with counseling. This shows that Sublocade isn’t a standalone cure but a powerful tool within a complete treatment program that includes counseling and psychosocial support, as recommended by the Substance Abuse and Mental Health Services Administration’s buprenorphine quick start guide.
Side effects of buprenorphine treatment
It’s completely normal to have questions about potential side effects when considering a new medication. Being informed helps you and your healthcare provider work together to manage your health. Like any medication, Sublocade has a range of possible side effects, from common and manageable to rare and serious.
First, it’s important to understand the most serious warning associated with Sublocade. The FDA has issued a boxed warning, its strongest caution, stating that the injection must never be administered into a vein. Doing so could cause serious harm or even death. This is why it must be administered by a qualified healthcare provider. According to the official FDA label, common side effects are generally mild to moderate. In clinical trials, the most frequently reported side effects included:
- Constipation
- Headache
- Nausea and vomiting
- Fatigue or tiredness
- Pain, itching, or redness at the injection site
- Increased liver enzymes
While most side effects are manageable, you should seek immediate medical help if you experience signs of a serious allergic reaction, such as trouble breathing, swelling of your face or throat, or a severe rash. Open communication with your provider about any side effects is key to ensuring your treatment is both safe and effective.
Warnings and precautions
Your safety is the top priority during recovery, and that means being aware of important warnings and precautions before starting Sublocade. It’s essential to have an open conversation with your healthcare provider about your full medical history and any other substances you use, including alcohol, prescription medications, and over-the-counter drugs.
One of the most significant risks is the potential for severe, life-threatening breathing problems if Sublocade is combined with other central nervous system depressants. You should avoid drinking alcohol and taking benzodiazepines (like Xanax or Valium) or sleep medications while on Sublocade unless specifically directed by your provider.
For women who are pregnant or planning to become pregnant, it’s crucial to know that using Sublocade can cause the baby to be born with neonatal opioid withdrawal syndrome (NOWS), which requires medical treatment. Other important warnings include the potential for liver problems, adrenal insufficiency, and the development of physical dependence. Providing your doctor with a complete picture of your health allows them to create the safest and most effective treatment plan for you.
Understanding cost and insurance coverage
Worries about the cost of treatment should never be a barrier to getting the help you deserve. For many, Sublocade is more affordable than you might think. The great news is that coverage is widespread; in fact, 88% of people with insurance have coverage for Sublocade. For those with public insurance, the numbers are even more encouraging, with almost 90% of people on Medicaid paying $0 for their treatment.
If you have commercial insurance, you may be wondering what the out-of-pocket costs will be. The Sublocade Copay Assistance Program is designed to help with just that. This program helps eligible patients with their copays, and currently, 95% of people enrolled in the program pay $0. Of course, the final cost will always depend on your specific insurance plan, but you don’t have to figure it out alone. Our team is here to help you navigate your insurance benefits and understand all your options.
Commercial insurance
If you have commercial insurance, there’s a strong chance that Sublocade is covered under your plan. Many policies recognize it as a valuable treatment for opioid use disorder. To help with any out-of-pocket costs, the manufacturer offers a Copay Assistance Program. We can help you check your eligibility and enroll, which could significantly lower or even eliminate what you have to pay.
Medicare
For those with Medicare, coverage for Sublocade often falls under Part B (as a medication administered in a clinical setting) or sometimes Part D, depending on your specific plan. Because Medicare plans can vary, it’s important to review your policy’s formulary and coverage rules. Our admissions team can assist you in verifying your Medicare benefits to determine your exact insurance coverage.
Uninsured
Please don’t let a lack of insurance stop you from seeking help. There is still hope and there are resources available. You may be eligible for a state-funded program like Medicaid, which provides excellent coverage for Sublocade. We can help you explore these options and see if you qualify. We also offer private pay options and can connect you with other resources to make treatment possible.
Frequently asked questions
Unlike oral buprenorphine or transmucosal buprenorphine that must be taken daily, Sublocade is administered once a month as a single dose. Most patients first begin taking buprenorphine in oral form before receiving their first injection. The maintenance dose is then given monthly by a healthcare professional. The key difference is convenience and steady medication levels in the body, which may help reduce cravings and lower the risk of missed doses. Physicians may recommend this long acting injectable option for patients who benefit from consistent medication administration.
The first injection is typically given in the abdomen, not the upper arm, as a subcutaneous injection under the skin. Some patients experience mild injection site reactions such as pain, redness, or swelling. These adverse events are usually manageable, but patients should talk to their healthcare provider about anything that feels severe or not normal. Because buprenorphine affects the brain and body, it is important to avoid alcohol and other drugs unless prescribed. Clinical monitoring helps ensure safety and tolerability throughout treatment.
As with any medication used for opioid addiction treatment, there are risks. Possible adverse events include withdrawal symptoms if other opioids are used, breathing problems, and, in rare cases, overdose or death, especially if mixed with alcohol or certain other drugs. Pregnant women and women of childbearing age should talk with their healthcare professional about the benefits and potential harm. Patients with severe OUD should follow their prescribed treatment plan closely and maintain regular contact with their provider to reduce serious harm.
Learning if buprenorphine treatment is right for you
Here at Red Ribbon Recovery, we offer access to Sublocade within recommended comprehensive outpatient programs (IOP and PHP). This means you get the benefit of the medication alongside essential one-on-one counseling, group therapy, and the invaluable support of a peer community that understands what you’re going through. Your treatment provider will work with you to create a plan that nurtures your whole self, mind, body, and spirit.
Taking this next step can feel overwhelming, but you don’t have to do it alone. We are here to walk with you, answer your questions, and help you build a future free from addiction. If you’re ready to explore your options, we encourage you to start a confidential conversation with our team. You can reach out to us by calling (888) 899-3880 or contact us. Your journey to a stronger, healthier life can start today. We at Red Ribbon Recovery are ready to help.
Sources
- Substance Abuse and Mental Health Services Administration. Buprenorphine quick start guide. SAMHSA.
- U.S. Food and Drug Administration. Sublocade. U.S. Food and Drug Administration.
- National Library of Medicine (U.S.). (June 19, 2019). SUBLOCADE rapid initiation study. ClinicalTrials.gov.
- National Library of Medicine (U.S.). (October 14, 2025). Rapid vs standard induction to injectable extended-release buprenorphine. PubMed Central.
- Rutgers, The State University of New Jersey. Using injectable buprenorphine (Sublocade). Rutgers MAT COE Center.
- National Library of Medicine (U.S.). (August 22, 2022). Injection site reaction to extended-release buprenorphine. PubMed Central.
- Substance Abuse and Mental Health Services Administration. SAMHSA’s working definition of recovery. SAMHSA.
- U.S. Department of Health and Human Services. (July 8, 2020). Models for medication-assisted treatment for opioid use disorder: Retention and continuity of care. ASPE.
- National Association of Addiction Treatment Providers. Addiction treatment outcomes and surveys. NAATP.
